Search

Displaying results 4031 - 4040 of 10000 in total
  1. Drug

    Pivmecillinam

    go.drugbank.com/drugs/DB01605
    ApprovedInvestigational

    Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. … It is active against gram-negative organisms and used as for amdinocillin. [PubChem]

  2. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. … Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae).

  3. Drug

    V1003

    go.drugbank.com/drugs/DB05046
    Experimental

    V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. … Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both

  4. Drug

    Lyme disease vaccine (recombinant OspA)

    go.drugbank.com/drugs/DB00045
    ApprovedWithdrawn

    Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.

  5. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.

  6. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

  7. Drug

    APD668

    go.drugbank.com/drugs/DB05166
    Experimental

    APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

  8. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is being developed by Rinat and is currently in Phase I clinical trials. … RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain.

  9. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. … It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer.

  10. Drug

    Clenoliximab

    go.drugbank.com/drugs/DB06241
    Experimental

    Clenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.